Using monocytes isolated from clinically stable patients homozygous for the common Phe508del CF mutation, we examined whether the in vitro application of clinically approved CFTR modulator combinations (IVA/LUM and IVA/TEZ), could also regulate IL-18 and IL-1β levels. Here, IL18 is linked to cystic fibrosis.